Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 139, Issue -, Pages 168-176Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2019.03.021
Keywords
Antibody-drug conjugates; Immunoconjugates; ADC stability; ADC components; Formulation strategy; Analytics
Categories
Ask authors/readers for more resources
The number of antibody-drug conjugates (ADCs) on the market is expected to multiply in the upcoming years. The main reason: this novel drug delivery system combines the benefits of the selectivity of the antibody and the potency of the cytotoxic agent. The interplay of the antibody, linker and payload, however, calls for a stable and unique formulation. In this review, the literature on the stability of marketed ADCs and the respective formulations are summarized and used as a basis to give general formulation considerations for ADCs. Whereas the same excipients are used as in antibody formulations, specific focus is on the ionic strength and concentrations of the excipients of the ADC. Further, a short outline of the analytical toolbox to characterize ADC formulations is included.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available